What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

(2009) · PubMed Central · Cited by 44,859 · see citing works

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,607 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955 · see citing works

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · see citing works

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Fossella, F. V., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V. A., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 938 · see citing works

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930 · see citing works

Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution

Buccheri, G., Ferrigno, D., & Tamburini, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00664-8 · Cited by 627 · see citing works

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612 · see citing works

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604 · see citing works

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Quoix, E., Zalcman, G., Oster, J.-P., Westeel, V., Pichon, E., Lavolé, A., Dauba, J., Debieuvre, D., Souquet, P.-J., Bigay-Game, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60780-0 · Cited by 566 · see citing works

Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2

Stanley, K. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.25 · Cited by 564 · see citing works

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

Lilenbaum, R., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 443 · see citing works

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H.-N., Pirker, R., Berthet, P., Breau, J. L., LIANES, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299 · see citing works

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

Klastersky, J. A., Sculier, J., Lacroix, H., Dabouis, G., Bureau, G., Libert, P., Richez, M., Ravez, P., Vandermoten, G., & Thiriaux, J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1556 · Cited by 246 · see citing works

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2

Zukin, M., Barrios, C. H., Rodrigues Pereira, J., De Albuquerque Ribeiro, R., de Mendonça Beato, C. A., do Nascimento, Y. N., Murad, A., Franke, F. A., Precivale, M., de Lima Araujo, L. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1911 · Cited by 235 · see citing works

Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

Beltran, P. J., Mitchell, P., Moody, G. E., Chung, Y., Cajulis, E. E., Belmontes, B., Radinsky, R., & Calzone, F. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4617 · Cited by 235 · see citing works

Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer

Reynolds, C. H., Obasaju, C. K., Schell, M. J., Li, X., Zheng, Z., Boulware, D. C., Caton, J. R., DeMarco, L. C., O’Rourke, M. A., Wright, G. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9766 · Cited by 172 · see citing works

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel

Gridelli, C., Ardizzoni, A., Chevalier, T. L., Manegold, C., Perrone, F., Thatcher, N., van Zandwijk, N., Maïo, M. D., Martelli, O., & de Marinis, F. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh087 · Cited by 162 · see citing works

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

Zatloukal, P., Petruzelka, L. B., Zemanová, M., Kolek, V., Skřičková, J., Pešek, M., Fojtů, H., Grygárková, I., Sixtová, D., Roubec, J., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00233-2 · Cited by 159 · see citing works

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

Bronte, G., Rizzo, S., Paglia, L. L., Adamo, V., Siragusa, S. M., Ficorella, C., Santini, D., Bazan, V., Colucci, G., Gebbia, N., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70016-5 · Cited by 140 · see citing works

Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

Castria, T. B. D., da Silva, E. M., de Góis, A. F. T., & Riera, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009256.pub2 · Cited by 122 · see citing works

Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer

Mazzanti, P., Massacesi, C., Rocchi, M., Mattioli, R., Lippe, P., Trivisonne, R., Buzzi, F., Signoribus, G. D., Tuveri, G., Rossi, G. E., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00140-5 · Cited by 77 · see citing works

Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung Cancer

Chevalier, T. L., Brisgand, D., Soria, J., Douillard, J., Pujol, J. L., Ruffié, P., Aberola, V., & Cigolari, S. (2001) · The Oncologist · doi:10.1634/theoncologist.6-suppl_1-8 · Cited by 68 · see citing works

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial

Paccagnella, A., Favaretto, A. G., Oniga, F., Barbieri, F., Ceresoli, G. L., Torri, V., Villa, E., Verusio, C., Cetto, G., Santo, A., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00280-0 · Cited by 66 · see citing works

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Viganò, M. G., Bianco, R., Barbera, S., Cavanna, L., De Marinis, F., Montesarchio, V., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.008 · Cited by 53 · see citing works

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

Jelić, S., Mitrović, L., Radosavljevic, D. Z., Elezar, E., Babović, N. L., Kovčin, V., Tomašević, Z., Kovačević, S., Gavrilović, D., & Radulovic, S. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00239-2 · Cited by 44 · see citing works

Gemcitabine versus Gemcitabine???Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group

Kosmidis, P., Dimopoulos, M. A., Syrigos, K., Nicolaides, C., Aravantinos, G., Boukovinas, I., Pectasides, D. G., Fountzilas, G., Bafaloukos, D. I., Bacoyiannis, C., et al. (2007) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30041-1 · Cited by 43 · see citing works

Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status

Kelly, K. L. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.003 · Cited by 32 · see citing works

Gemcitabine‐based doublets versus single‐agent therapy for elderly patients with advanced nonsmall cell lung cancer

Russo, A. D., Rizzo, S., Fulfaro, F., Adamo, V., Santini, D., Vincenzi, B., Gebbia, N., & Carreca, I. U. (2009) · Cancer · doi:10.1002/cncr.24207 · Cited by 23 · see citing works

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer

Paccagnella, A., Favaretto, A. G., Oniga, F., Barbieri, F., Ceresoli, G. L., Torri, V., Villa, E., Verusio, C., Cetto, G., Santo, A., et al. (2004) · Cited by 20 · see citing works

Treatment of non-small cell lung cancer patients with performance status2 (PS2)

Boukovinas, I., & Kosmidis, P. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.016 · Cited by 14 · see citing works

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Ramalingam, S. S., & Khuri, F. R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0190 · Cited by 14 · see citing works

Treatment of Patients with Advanced Lung Cancer and Poor Performance Status

Lilenbaum, R. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.017 · Cited by 11 · see citing works

Lung cancer in the elderly: what's age got to do with it?

Owonikoko, T. K., Ramalingam, S. S., & Khuri, F. R. (2010) · PubMed · Cited by 3 · see citing works

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · see citing works

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 644 · see citing works

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works

Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

Rossi, A., & Maïo, M. D. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 246 · see citing works

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Lee, S. M., Schulz, C. K. J., Prabhash, K., Kowalski, D. M., Szczęsna, A., Han, B., Rittmeyer, A., Talbot, T., Vicente, D., Califano, R., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00774-2 · Cited by 169 · see citing works

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines

Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 46 · see citing works

Treatment of advanced non-small-cell lung cancer

Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46 · see citing works

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

Lobefaro, R., Viscardi, G., Liello, R. D., Massa, G., Iacovino, M. L., Sparano, F., Corte, C. M. D., Ferrara, R., Signorelli, D., Proto, C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.027 · Cited by 35 · see citing works

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy

Banna, G. L., Camerini, A., Bronte, G., Anile, G., Addeo, A., Rundo, F., Zanghì, G., Lal, R., & Libra, M. (2018) · Anticancer Research · doi:10.21873/anticanres.12647 · Cited by 35 · see citing works

Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?

Frega, S., Maso, A. D., Ferro, A., Bonanno, L., Conte, P., & Pasello, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.012 · Cited by 24 · see citing works

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: the THOCOoP cooperative group

Arrieta, O. G., Cardona, A. F., Lara‐Mejía, L., Heredia, D., Barrón, F., Zatarain-Barrón, Z. L., Lozano, F., de Lima, V. C. C., Maldonado, F., Corona-Cruz, J. F., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103033 · Cited by 19 · see citing works

Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups

Sheffield, K. M., Bowman, L., Smith, D. M., Li, L., Hess, L. M., Montejano, L. B., Willson, T. M., & Davidoff, A. J. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0040 · Cited by 14 · see citing works

Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?

Bronte, G., Passiglia, F., Galvano, A., & Russo, A. G. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1075000 · Cited by 14 · see citing works

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update

Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13 · see citing works

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

Bronte, G., Cosi, D. M., Magri, C., Frassoldati, A., Crinò, L., & Calabrò, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612622 · Cited by 10 · see citing works

Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., van der Wekken, A. J., & van Geffen, W. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013382.pub2 · Cited by 8 · see citing works

Cytotoxic chemotherapy in advanced non–small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice

Kancharla, H., Naresh, G., Pathak, N., Vandidassane, I., Khurana, S., Pushpam, D., Jain, D., Kumar, S., Pathy, S., Mohan, A., et al. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100550 · Cited by 9 · see citing works

Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

Yélamos, J., Galindo, M., Navarro, J., Albanell, J., Rovira, A., Rojo, F., & Oliver, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1065370 · Cited by 8 · see citing works

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Carter, C. A., Zeman, K. G., Day, R. M., Richard, P., Oronsky, A. L., Oronsky, N. C., Lybeck, M., Scicinski, J. J., & Oronsky, B. T. (2016) · Oncotarget · doi:10.18632/oncotarget.8205 · Cited by 8 · see citing works

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

Bronte, G., Franchina, T., Alù, M., Sortino, G., Celesia, C., Passiglia, F., Savio, G., Laudani, A., Russo, A., Picone, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8130 · Cited by 8 · see citing works

Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line

Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6 · see citing works

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report

Cosi, D. M., Fragale, C., Magri, C., Carnevale, A., Ciancetta, A., Guidoboni, M., Negrini, M., Bronte, G., & Calabrò, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147508 · Cited by 3 · see citing works

Precision medicine in cancer: beyond wishful thinking?

Peters, G. J. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1140555 · Cited by 2 · see citing works

Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426

Ichikawa, Y., Seki, N., Honda, T., Sakugawa, M., Hosokawa, S., Bessho, A., Agemi, Y., Shimokawa, T., Otani, S., Nakahara, Y., et al. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2144 · Cited by 1 · see citing works

Les patients avec indice de performance supérieur à 1

Berghmans, T. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30062-9

Populations particulières : patients de Performance Status 2 ou plus

Gounant, V., Soussi, G., Pluvy, J., Brosseau, S., Hachon, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30107-5

Recomendaciones de oncólogos que trabajan en el ISSSTE para el tratamiento sistémico del cáncer de pulmón avanzado 2020

Aldaco-Sarvide, F., Valle-Solís, A. A. E., Acosta-Gutiérrez, D. N., Añorve-Bailón, D., Ballesteros-Pino, D. A., Cervantes-Sánchez, G., Cárdenas-Cárdenas, E., Cruz-López, J. C., Díaz-Alvarado, M. G., Durán-Gil, C., et al. (2020) · Latin American Journal of Clinical Sciences and Medical Technology · doi:10.34141/ljcs7299157

Populations particulières : patients de Performance Status 2 ou plus

Gounant, V., Brosseau, S., Bizot, A., Vauchier, C., Khrouf, S., Hachon, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00137-9

Populations particulières : patients de performance status 2 ou plus

Gounant, V., Brosseau, S., Guezour, N., Vauchier, C., Ferreira, D. L., Nicolas, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00167-2

Populations particulières : Patients de Performance Status 2 et plus

Gounant, V., Alvarez, L., Xu, Y. M., Mehlman, C., Nicolas, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00091-6

Systematic review:comparison of Platinum-based doublet versus non-Platinum single-agent as second-line treatment of advanced non-small cell lung cancer

Yue, W. (2015) · Zhonghua zhongliu fangzhi zazhi · Cited by 1 · see citing works

Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh476 · Cited by 97 · see citing works

Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis

Qiu, H., Wang, F., Guo, G., Zhou, F., He, W., & Xia, L. (2011) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-011-0745-3

Triplets vs. doublets in the management of advanced non-small cell lung cancer (NSCLC) using third generation chemotherapeutic agents: A meta-analysis

Azim, H. A., Ganti, A. K., Elattar, I. A., Azim, H. A., & Loberiza, F. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7580 · Cited by 4 · see citing works

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F. M., Gebbia, V., Smit, E. F., Morabito, A., Gallo, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5844 · Cited by 181 · see citing works